173,361 results

#114472-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-mCherry (#114472). In addition to the viral particles, you will also receive purified pAAV-hSyn-mCherry plasmid DNA. Synapsin-driven mCherry control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 5, 2023

Academic Institutions and Nonprofits only

#26971-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-eNpHR 3.0-EYFP (#26971). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-eNpHR 3.0-EYFP plasmid DNA. CaMKIIa-driven eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 30, 2018

Academic Institutions and Nonprofits only

#62723-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] (#62723). In addition to the viral particles, you will also receive purified pAAV-Syn-FLEX-rc[ChrimsonR-tdTomato] plasmid DNA. Cre-dependent expression of ChrimsonR-tdTomato under the control of the Synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Sept. 27, 2024

Academic Institutions and Nonprofits only

#105551-AAV9

Ready-to-use AAV9 particles produced from pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 (#105551). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII.HI.GFP-Cre.WPRE.SV40 plasmid DNA. Expression of GFP-Cre from CamKII promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Aug. 2, 2018

Academic Institutions and Nonprofits only

#87306-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV pEF1a-DIO-FLPo-WPRE-hGHpA (#87306). In addition to the viral particles, you will also receive purified AAV pEF1a-DIO-FLPo-WPRE-hGHpA plasmid DNA. EF1a-driven, Cre dependent expression of the site-specific recombinase FlpO. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Li Zhang

Zingg et al Neuron. 2017 Jan 4;93(1):33-47. doi: 10.

July 22, 2020

Academic Institutions and Nonprofits only

#104491-AAV9

Ready-to-use AAV9 particles produced from pGP-AAV-syn-FLEX-jGCaMP7s-WPRE (#104491). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7s-WPRE plasmid DNA. Synapsin-driven, Cre-dependent, GCaMP7s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Aug. 7, 2018

Academic Institutions and Nonprofits only

#114470-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-mCherry (#114470). In addition to the viral particles, you will also receive purified pAAV-Ef1a-mCherry plasmid DNA. EF1a-driven mCherry expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#213940-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_dTomato_nlsdTomato (#213940). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only